The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapyClaire S. Reader(Queen Mary University of London), John F. Marshall(Queen Mary University of London)The Journal of PathologyJuly 1, 201910.1002/path.5320Cited by 109SaveCiteExport RISWatch citationsRelated PapersIntegrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus|Theranostics|2020|49Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer|Pancreatology|2024|12The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells Against Pancreatic Cancer in an Immunocompetent Model|Cancers|2025|1